<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>03770026953082</udiDi>
    <basicUdiDi>B-03770026953082</basicUdiDi>
    <tradeName>Genexpath</tradeName>
    <deviceName>RT-MIS</deviceName>
    <manufacturerName>Genexpath</manufacturerName>
    <manufacturerSrn>FR-MF-000029325</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W02050192</emdnCode>
    <emdnDescription>NUCLEIC ACID TESTING INSTRUMENTS EXCEPT MICRO-ARRAYS - IVD MEDICAL DEVICE SOFTWARE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>RT-MIS</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T19:33:47.440Z</lastUpdated>
  </row>
  <row>
    <udiDi>03770026953075</udiDi>
    <basicUdiDi>B-03770026953075</basicUdiDi>
    <tradeName>Genexpath</tradeName>
    <deviceName>SarcomaFusion 48U</deviceName>
    <manufacturerName>Genexpath</manufacturerName>
    <manufacturerSrn>FR-MF-000029325</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>GEP-SF48</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T19:33:46.622Z</lastUpdated>
  </row>
  <row>
    <udiDi>03770026953068</udiDi>
    <basicUdiDi>B-03770026953068</basicUdiDi>
    <tradeName>Genexpath</tradeName>
    <deviceName>SarcomaFusion 24U</deviceName>
    <manufacturerName>Genexpath</manufacturerName>
    <manufacturerSrn>FR-MF-000029325</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>GEP-SF24</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T19:33:45.861Z</lastUpdated>
  </row>
  <row>
    <udiDi>03770026953051</udiDi>
    <basicUdiDi>B-03770026953051</basicUdiDi>
    <tradeName>Genexpath</tradeName>
    <deviceName>SarcomaFusion 16U</deviceName>
    <manufacturerName>Genexpath</manufacturerName>
    <manufacturerSrn>FR-MF-000029325</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>GEP-SF16</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T19:33:45.035Z</lastUpdated>
  </row>
  <row>
    <udiDi>03770026953044</udiDi>
    <basicUdiDi>B-03770026953044</basicUdiDi>
    <tradeName>Genexpath</tradeName>
    <deviceName>SarcomaFusion 8U</deviceName>
    <manufacturerName>Genexpath</manufacturerName>
    <manufacturerSrn>FR-MF-000029325</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>GEP-SF08</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T19:33:41.031Z</lastUpdated>
  </row>
  <row>
    <udiDi>03770026953037</udiDi>
    <basicUdiDi>B-03770026953037</basicUdiDi>
    <tradeName>Genexpath</tradeName>
    <deviceName>LymphoSign 48U</deviceName>
    <manufacturerName>Genexpath</manufacturerName>
    <manufacturerSrn>FR-MF-000029325</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>GEP-LS48</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T19:33:40.236Z</lastUpdated>
  </row>
  <row>
    <udiDi>03770026953020</udiDi>
    <basicUdiDi>B-03770026953020</basicUdiDi>
    <tradeName>Genexpath</tradeName>
    <deviceName>LymphoSign 24U</deviceName>
    <manufacturerName>Genexpath</manufacturerName>
    <manufacturerSrn>FR-MF-000029325</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>GEP-LS24</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T19:33:39.417Z</lastUpdated>
  </row>
  <row>
    <udiDi>03770026953013</udiDi>
    <basicUdiDi>B-03770026953013</basicUdiDi>
    <tradeName>Genexpath</tradeName>
    <deviceName>LymphoSign 16U</deviceName>
    <manufacturerName>Genexpath</manufacturerName>
    <manufacturerSrn>FR-MF-000029325</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>GEP-LS16</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T19:33:38.618Z</lastUpdated>
  </row>
  <row>
    <udiDi>03770026953006</udiDi>
    <basicUdiDi>B-03770026953006</basicUdiDi>
    <tradeName>Genexpath</tradeName>
    <deviceName>LymphoSign 8U</deviceName>
    <manufacturerName>Genexpath</manufacturerName>
    <manufacturerSrn>FR-MF-000029325</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>GEP-LS08</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T19:33:34.627Z</lastUpdated>
  </row>
</eudamedExport>